MedPath

Jiangsu Hengrui Medicine Co., Ltd

🇨🇳China
Ownership
-
Established
1970-01-01
Employees
-
Market Cap
$38.9B
Website
http://www.hrs.com.cn/english/

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Phase 1
Active, not recruiting
Conditions
Mature B Cell Neoplasms
Interventions
First Posted Date
2018-09-10
Last Posted Date
2022-11-14
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
86
Registration Number
NCT03664297
Locations
🇨🇳

Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Phase 2
Terminated
Conditions
Metastatic Colorectal Cancer
Interventions
First Posted Date
2018-08-24
Last Posted Date
2019-05-10
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
12
Registration Number
NCT03645876
Locations
🇨🇳

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

The PK/PD Study of SHR0532 Tablets in Healthy Subjects

Phase 1
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2018-08-24
Last Posted Date
2018-08-24
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
50
Registration Number
NCT03645278

The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects

Phase 1
Completed
Conditions
Hypercholesteremia
Interventions
Drug: Placebo
First Posted Date
2018-08-16
Last Posted Date
2022-08-03
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
32
Registration Number
NCT03634436
Locations
🇨🇳

FuWai Hospital , Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Phase 3
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Drug: Placebo
Drug: FOLFOX4
First Posted Date
2018-07-30
Last Posted Date
2022-02-10
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
396
Registration Number
NCT03605706
Locations
🇨🇳

81 Hospital Nanjing, Nanjing, Jiangsu, China

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Phase 1
Active, not recruiting
Conditions
Relapsed or Refractory Mature Lymphoid Neoplasms
Interventions
First Posted Date
2018-07-27
Last Posted Date
2024-10-01
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
272
Registration Number
NCT03603951
Locations
🇨🇳

Beijing Cancer Hospital, Peking University, Beijing, Beijing, China

A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics

Phase 1
Completed
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2018-07-27
Last Posted Date
2019-05-07
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
15
Registration Number
NCT03603132
Locations
🇨🇳

The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China

SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer

Phase 1
Terminated
Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
First Posted Date
2018-07-24
Last Posted Date
2022-09-01
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
4
Registration Number
NCT03596658
Locations
🇨🇳

The 307th Hospital of Military Chinese People's Liberation Army, Beijing, Beijing, China

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Phase 3
Conditions
HER2-positive Breast Cancer
Interventions
First Posted Date
2018-07-17
Last Posted Date
2021-08-04
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
355
Registration Number
NCT03588091
Locations
🇨🇳

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

🇨🇳

Huai'an First People's Hospital, Huaian, Jiangsu, China

🇨🇳

The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China

and more 14 locations

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Phase 2
Completed
Conditions
Nasopharyngeal Carcinoma
Interventions
First Posted Date
2018-06-15
Last Posted Date
2024-03-15
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
156
Registration Number
NCT03558191
Locations
🇨🇳

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath